Huijbers Elisabeth J M, Griffioen Arjan W
a Angiogenesis Laboratory, Department of Medical Oncology , VU University Medical Center , Amsterdam , The Netherlands.
Hum Vaccin Immunother. 2017 May 4;13(5):1112-1114. doi: 10.1080/21645515.2016.1276140. Epub 2017 Jan 24.
In light of the increasing number of approved monoclonal antibodies for the treatment of cancer, it seems peculiar that the development of antibody inducing vaccines gets so little attention. In our view there is a tremendous opportunity in the development of cancer vaccines inducing humoral immune responses, involving a couple of major advantages. Firstly, the effectivity of a polyclonal antibody response is expected to exceed the one of monoclonal antibodies. This is supported by preclinical data that show pronounced anti-tumor responses and early clinical trials in which benefit is observed in patients with advanced cancer. Secondly, vaccination strategies are expected to reduce hospital visits, resulting in enhanced quality of life. And last but not least, vaccination strategies are extremely cost effective, alleviating the socioeconomic problems of prohibitively high drug costs. To reach further clinical success, efforts should focus on target identification, optimization of vaccination strategies and adjuvant development.
鉴于获批用于治疗癌症的单克隆抗体数量不断增加，抗体诱导疫苗的研发却如此不受关注，这似乎有些奇怪。我们认为，研发能诱导体液免疫反应的癌症疫苗存在巨大机遇，这有几个主要优势。首先，多克隆抗体反应的有效性预计会超过单克隆抗体。临床前数据支持这一点，这些数据显示出显著的抗肿瘤反应，早期临床试验也观察到晚期癌症患者从中受益。其次，疫苗接种策略预计会减少医院就诊次数，从而提高生活质量。最后但同样重要的是，疫苗接种策略极具成本效益，可缓解药物成本过高带来的社会经济问题。为了取得进一步的临床成功，应将努力集中在靶点识别、疫苗接种策略优化和佐剂研发上。
